CME Group Inc. (NASDAQ:CME) has been given an average rating of “Buy” by the ten analysts that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $135.14.

CME has been the topic of a number of recent analyst reports. Royal Bank Of Canada set a $130.00 price target on CME Group and gave the company a “buy” rating in a report on Monday, June 12th. UBS AG reissued a “buy” rating and set a $134.00 price target (down from $136.00) on shares of CME Group in a report on Monday, June 5th. Citigroup Inc. initiated coverage on CME Group in a report on Wednesday, July 12th. They set a “buy” rating and a $140.00 price target on the stock. Jefferies Group LLC reissued a “buy” rating and set a $128.00 price target on shares of CME Group in a report on Monday, July 10th. Finally, Deutsche Bank AG decreased their price target on CME Group from $139.00 to $136.00 and set a “buy” rating on the stock in a report on Tuesday, July 4th.

COPYRIGHT VIOLATION WARNING: “CME Group Inc. (CME) Given Average Rating of “Buy” by Analysts” was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another website, it was stolen and reposted in violation of U.S. and international copyright law. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/09/17/cme-group-inc-cme-given-average-rating-of-buy-by-analysts.html.

CME Group (NASDAQ:CME) traded down 0.63% during trading on Friday, reaching $131.29. The company had a trading volume of 1,670,615 shares. The firm has a market capitalization of $44.63 billion, a P/E ratio of 26.80 and a beta of 0.72. CME Group has a one year low of $98.95 and a one year high of $132.34. The firm’s 50-day moving average price is $126.18 and its 200 day moving average price is $122.07.

CME Group (NASDAQ:CME) last posted its quarterly earnings results on Tuesday, August 1st. The financial services provider reported $1.23 EPS for the quarter, beating the Zacks’ consensus estimate of $1.20 by $0.03. The business had revenue of $925.00 million for the quarter, compared to analysts’ expectations of $931.05 million. CME Group had a return on equity of 7.61% and a net margin of 46.05%. The business’s quarterly revenue was up 2.1% on a year-over-year basis. During the same period last year, the firm earned $1.14 earnings per share. Equities analysts forecast that CME Group will post $4.81 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Monday, September 25th. Stockholders of record on Friday, September 8th will be issued a $0.66 dividend. The ex-dividend date is Thursday, September 7th. This represents a $2.64 annualized dividend and a dividend yield of 2.01%. CME Group’s dividend payout ratio (DPR) is 53.99%.

In related news, CFO John W. Pietrowicz sold 2,500 shares of CME Group stock in a transaction dated Monday, July 10th. The stock was sold at an average price of $124.50, for a total value of $311,250.00. Following the completion of the transaction, the chief financial officer now owns 38,495 shares in the company, valued at $4,792,627.50. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, President Bryan T. Durkin sold 9,200 shares of CME Group stock in a transaction dated Tuesday, August 8th. The stock was sold at an average price of $125.13, for a total value of $1,151,196.00. Following the completion of the transaction, the president now owns 70,938 shares of the company’s stock, valued at approximately $8,876,471.94. The disclosure for this sale can be found here. Insiders sold 48,244 shares of company stock worth $6,021,890 over the last ninety days. Insiders own 0.57% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CME. Fiduciary Trust Co. purchased a new position in CME Group in the second quarter worth about $105,000. Quadrant Capital Group LLC grew its position in CME Group by 13.6% in the second quarter. Quadrant Capital Group LLC now owns 944 shares of the financial services provider’s stock worth $111,000 after acquiring an additional 113 shares in the last quarter. Parallel Advisors LLC grew its position in CME Group by 4.1% in the first quarter. Parallel Advisors LLC now owns 1,084 shares of the financial services provider’s stock worth $128,000 after acquiring an additional 43 shares in the last quarter. San Francisco Sentry Investment Group CA purchased a new position in CME Group in the second quarter worth about $129,000. Finally, Whittier Trust Co. grew its position in CME Group by 2.6% in the second quarter. Whittier Trust Co. now owns 1,057 shares of the financial services provider’s stock worth $133,000 after acquiring an additional 27 shares in the last quarter. Institutional investors own 82.67% of the company’s stock.

About CME Group

CME Group Inc, through its exchanges, provides products across all asset classes, including futures and options based on interest rates, equity indexes, foreign exchange, energy, agricultural products and metals. The Company’s segment primarily consists of the Chicago Mercantile Exchange Inc (CME), Board of Trade of the City of Chicago, Inc (CBOT), New York Mercantile Exchange, Inc (NYMEX) and Commodity Exchange, Inc (COMEX) exchanges.

Analyst Recommendations for CME Group (NASDAQ:CME)

Receive News & Ratings for CME Group Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CME Group Inc. and related companies with MarketBeat.com's FREE daily email newsletter.